|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Stage  (number) | % Overall  Survival  at 24 months  (95% CI) | Disease recurrence in those treated radically (number) | | Treatment  modality  (number) | % Overall  Survival  at 24 months  (95% CI) |
| Loco-regional only | Distal +/- locoregional |
| Stage 1-2  n=16 | 67.5  (38.3 – 85.1) | 2/12 | 1/12 | Surgery  (n=2) | 100 |
| Surgery +adjuvant RT  (n=1) | 100 |
| RT alone  (n=9) | 64.8  (25.3-87.2) |
| BSC  (n=4) | 50.0  (5.8-84.5) |
| Stage 3  N=15 | 58.3  (29.3 – 78.9) | 3/12 | 0/12 | Surgery  (n=2) | 0 |
| Surgery +adjuvant RT  (n=1) | 100 |
| CRT  (n=6) | 83.3  (27.3-97.5) |
| RT alone  (n=3) | 0.0 |
| BSC  (n=3) | 0 |
| Stage 4  N=87 | 27.3  (17.8 – 39.0) | 5/33 | 2/33 | Surgery  (n=12) | 50.0  (20.8 to 73.6) |
| Surgery +adjuvant  (n=7) | 100.0 |
| CRT  (n=5) | 0.0 |
| XRT  (n=9) | 53.3  (12.5 to 82.7) |
| Palliative chemotherapy  (n=5) | 40.0  (5.2 to 75.3) |
| BSC  (n=49) | 7.7  (2.0 to 18.4) |

Table 2: Treatment modalities and outcomes